Skip to main content
  • Saved

made a Post

M3258 is a selective inhibitor of the immunoproteasome subunit LMP7 (β5i) delivering efficacy in multiple myeloma models - PubMed

M3258 is a selective inhibitor of the immunoproteasome subunit LMP7 (β5i) delivering efficacy in multiple myeloma models - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/34045234/

2021 May 27;molcanther.MCT-21-0005-A.2021. doi: 10.1158/1535-7163.MCT-21-0005. Online ahead of print. 1 Translational Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany michael.sanderson@merckgroup.com. 2 Merck KGaA. 3 Merck KGaA, Darmstadt, Germany. 4 Blood Systems Research Institute. 5 Oncology, Merck KGaA, Darmstadt, Germany. 6 Global Research and Development, Merck Serono.